Mild Cognitive Impairment Clinical Trial
Official title:
Hyperbaric Oxygen Therapy for Prodromal Alzheimer´s Disease With Cerebrovascular Disease: A Prospective, Randomized, Double Blind Study
NCT number | NCT05349318 |
Other study ID # | 254-21-ASF |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 31, 2022 |
Est. completion date | March 2025 |
Alzheimer´s disease is a devastating illness that effects the patients as well as their family members. Its prevalence increases exponentially and the burden on the healthcare system is enormous. AD neuropathology begins 15-20 years before the occurrence of cognitive symptoms, which ranges from preclinical stage to mild cognitive impairment (MCI) to dementia. Prodromal AD is an early stage of the disease which is characterized by positive biomarkers and MCI. To this day, there is no medication that can cure or halt the progression of the disease and most studies focus on finding reversible risk factors and changing their influence. Several aetiologies have been proposed, like the deposition of amyloid and tau proteins, neuroinflammation and cerebral ischemia due to cerebrovascular factors. The Amyloid deposition, which serves as the biological marker of AD, was originally thought to be the main cause of the disease, however, recent data suggests that it is not the cause and that it might actually has a protective role. On the other hand, it is known today that vascular changes with related tissue ischemia and neuroinflammation have a crucial role in the development of AD in many patients. These pathologies, ischemia & neuroinflammation, can be improved by the use of hyperbaric oxygen therapy (HBOT). The goal of this study is to explore the potential beneficial effect of HBOT on prodromal AD.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | March 2025 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Diagnosis of Mild cognitive impairment (MCI) due to AD or mixed AD and vascular dementia pathology 2. MMSE score of 20 and above 3. Stable psychological and pharmacological treatment for more than three months prior to inclusion. 4. Caregiver that is seeing the patient at least twice per week and is willing to participate and accompany the patient and fill questionnaires 5. Subject willing and able to read, understand and sign an informed consent Exclusion Criteria: 1. Inability to attend scheduled clinic visits and/or comply with the study protocol 2. History of traumatic brain injury, brain tumors, brain surgery, chronic subdural haemorrhages, Epilepsy 3. Active malignancy 4. Substance use at baseline, except for prescribed cannabis if vaporized or taken PO as tincture 5. History of other neurodegenerative diseases including Parkinson's disease (PD), Lewy body dementia (LBD), Frontotemporal dementia (FTD), Multiple sclerosis (MS), Amyotrophic lateral sclerosis (ALS), Creutzfeld Jacob disease (CJD), Multisystem atrophy (MSA), Pseudobulbar palsy (PSP), Corticobasal degeneration (CBD), Wernicke Korsakoff syndrome 6. Chronic use of medications that may compromise cognitive function and cannot be stopped: Anticonvulsants, Anticholinergics, antiparkinsonian, corticosteroids, Benzodiazepines 7. Moderate to severe sleep apnea with no use of CPAP 8. Diagnosis of a psychiatric disorder including: major depression, schizophrenia, bipolar disorder 9. Serious suicidal ideation 10. Renal or liver insufficiency, electrolyte imbalances 11. Chronic heart failure with ejection fraction of 35 or less 12. HBOT for any reason prior to study enrolment 13. Chest pathology incompatible with pressure changes (including active asthma or COPD) 14. Ear or Sinus pathology incompatible with pressure changes (above 3 otolaryngologist visits a year) 15. An inability to perform an awake brain MRI or Amyloid PET 16. An inability to perform computerized cognitive tests (Neurotrax) 17. MMSE score below 20 18. No evidence of amyloid in the brain PET 19. No evidence of vascular related lesions in the brain MRI 20. Active smoking 21. Participation in another study |
Country | Name | City | State |
---|---|---|---|
Israel | Shamir Medical Center (Assaf Harofeh) | Zerifin |
Lead Sponsor | Collaborator |
---|---|
Assaf-Harofeh Medical Center |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Quality of life SF-36 questionnaire | Self reported SF-36 quality of life questionnaire | At baseline, 3 months, 9 months | |
Other | The Pittsburgh Sleep Quality Index (PSQI) questionnaire | Self reported quality of sleep questionnaire | At baseline, 3 months, 9 months | |
Other | The Depression, Anxiety and Stress Scale-21 (DASS-21) | Self reported questionnaire of depression, anxiety and stress | At baseline, 3 months, 9 months | |
Other | Advanced Activities of Daily Function (a-ADL) | Questionnaire of activities of daily living for the patient and the informant | At baseline, 3 months, 9 months | |
Other | Clinical Dementia Rating (CDR) scale - sum of boxes | Cognitive assessment of 6 cognitive and functional domains, based on an interview of the patient and a reliable informant | At baseline, 3 months, 9 months | |
Other | Montreal Cognitive Assessment (MOCA) | Neurocognitive assessment | At baseline, 3 months, 9 months | |
Other | Mini Mental State Exam (MMSE) | Neurocognitive assessment | At baseline, 3 months, 9 months | |
Other | Serum inflammatory markers | Serum inflammatory markers include: IL-1, IL-6, tumor necrosis factor-alpha, hsCRP | At baseline, 3 months, 9 months | |
Other | Alzheimer's disease (AD) biomarkers: Abeta 42/40 | Plasma will be tested for Abeta 42/40 | At baseline, 3 months, 9 months | |
Other | Alzheimer's disease (AD) biomarkers: P-tau181 | Plasma will be tested for P-tau181 | At baseline, 3 months, 9 months | |
Other | Alzheimer's disease (AD) biomarkers: P-tau231 | Plasma will be tested for P-tau 231 | At baseline, 3 months, 9 months | |
Other | Alzheimer's disease (AD) biomarkers: neurofilament light (NfL) | Plasma will be tested for neurofilament light (NfL) | At baseline, 3 months, 9 months | |
Other | Alzheimer's disease (AD) biomarkers: plasma glial fibrillary acidic protein (GFAP) | Plasma will be tested for plasma glial fibrillary acidic protein (GFAP) | At baseline, 3 months, 9 months | |
Other | Vascular biomarker- Vascular endothelial growth factor (VEGF) | Serum will be tested for VEGF | At baseline, 3 months, 9 months | |
Other | Passive behavioral monitoring using BHQ smartphone application | An application will be installed on the participants' smartphones for continuous passive monitoring of human behavior | Through study completion, up to one year | |
Other | Cardiopulmonary exercise test (CPET) | CPET determines the anaerobic threshold that is expected to change through the intervention | At baseline, 3 months, 9 months | |
Other | Neuro-physical evaluation - Static balance | Static balance will be assessed by the Balance Error Scoring System (BESS) | At baseline, 3 months, 9 months | |
Other | Neuro-physical evaluation- Timed Up and Go test | Dynamic balance and risk of falling will be assessed by the Timed Up and Go test (TUG) | At baseline, 3 months, 9 months | |
Other | Neuro-physical evaluation - 10 meter walk | Dynamic balance and risk of falling will be assessed by 10-meter walk (10MW). | At baseline, 3 months, 9 months | |
Other | Neuro-physical evaluation - Sit to Stand test | Muscle function will be assessed by the sit to stand (STS) test for the leg strength and endurance | At baseline, 3 months, 9 months | |
Other | Neuro-physical evaluation - Hand held dynamometery | Muscle function will be assessed by the hand-held dynamometry (HHD) for the isometric grip strength. | At baseline, 3 months, 9 months | |
Other | Neuro-physical evaluation - 6 minute walk | The sub-maximal aerobic capacity and endurance will be assessed by the 6-minute walk test (6MWT). | At baseline, 3 months, 9 months | |
Other | Event-related synchronization (ERS) change - EEG | The EEG will include a three-level visual N-back task, and go-no-go task | At baseline, 3 months, 9 months | |
Other | Event-related desynchronization (ERD) change - EEG | The EEG will include a three-level visual N-back task, and go-no-go task | At baseline, 3 months, 9 months | |
Other | Grand average P300 ERP change - EEG | The EEG will include a three-level visual N-back task, and go-no-go task | At baseline, 3 months, 9 months | |
Other | Alpha band power change - EEG | The EEG will include a three-level visual N-back task, and go-no-go task | At baseline, 3 months, 9 months | |
Other | Beta band power change - EEG | The EEG will include a three-level visual N-back task, and go-no-go task | At baseline, 3 months, 9 months | |
Other | Gamma band power change - EEG | The EEG will include a three-level visual N-back task, and go-no-go task | At baseline, 3 months, 9 months | |
Other | Delta band power change - EEG | The EEG will include a three-level visual N-back task, and go-no-go task | At baseline, 3 months, 9 months | |
Other | Theta to alpha bands power ratio change - EEG | The EEG will include a three-level visual N-back task, and go-no-go task | At baseline, 3 months, 9 months | |
Other | N-back match/no match percentage change - EEG | The EEG will include a three-level visual N-back task, and go-no-go task | At baseline, 3 months, 9 months | |
Primary | Change from baseline of neurocognitive functions evaluation by Mindstreams cognitive battery test (Neurotrax) | Memory, attention and information process will be evaluated using the NeuroTrax computerized cognitive evaluation battery. | At baseline, 3 months | |
Primary | Change from baseline of neurocognitive functions evaluation by Mindstreams cognitive battery test (Neurotrax) | Memory, attention and information process will be evaluated using the NeuroTrax computerized cognitive evaluation battery. | 9 months | |
Secondary | Brain amyloid PET using Flumetamol (Vizamyl) tracer | Brain amyloid assessment using PET scan with Flumetamol (Vizamyl) tracer will be used to assess change in amyloid burden | At baseline, 3 months, 9 months | |
Secondary | Whole-brain quantitative perfusion imaging | Whole-brain quantitative perfusion imaging will be performed using Dynamic susceptibility contrast (DSC)-MRI technique | At baseline, 3 months, 9 months | |
Secondary | Brain microstructure MRI evaluation | Fractional anisotropy (FA) and Mean diffusivity (MD) will be evaluated using diffusion tensor imaging (DTI) MRI protocol | At baseline, 3 months, 9 months | |
Secondary | Brain volume MRI evaluation | Gray matter and hippocampal volumetric measurement using high-resolution MP-RAGE 3D MRI | At baseline, 3 months, 9 months | |
Secondary | Brain functional connectivity imaging | Resting state functional MRI | At baseline ,3 months, 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |